Blistex bolsters its product portfolio with growth brand from J&J

OAK BROOK, Ill. – Blistex on Tuesday announced the acquisition of the Tucks brand of OTC rectal medications from Johnson & Johnson Consumer.  

The transaction closed on July 8 for an undisclosed amount.

“We are delighted to welcome Tucks to the Blistex family of brands,” stated Justin Arch, CEO of Blistex.  “Given its efficacious products and strong heritage, Tucks is well positioned to address growing consumer needs within its category, and we expect it to respond positively to our focused model of consumer advertising and promotional support combined with thoughtful innovation.”

The brand is currently outpacing category growth, according to IRI data. For the 52 weeks ended May 15, Tucks generated $19.2 million on a 4.3% sales lift across total U.S. multi-outlet channels. The hemorrhoidal remedies category as a whole is up 1.6% to $117 million.

Blistex is best known as a global leader in lip care, offering a wide range of lip balms with highly effective formulas and unique added benefits under the Blistex brand.  Its broader consumer healthcare portfolio includes Odor Eaters, as well as mainstay brands in categories ranging from acne care with Stridex, oral analgesics with Kank-A and itch relief with Ivarest.  

Blistex also markets a full line of skin care products under the Glysomed brand that includes the top-selling hand cream in Canada.